Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 2, 2002 - Issue 1
Submit an article Journal homepage
22
Views
13
CrossRef citations to date
0
Altmetric
Review

Atypical antipsychotics: revolutionary or incremental advance?

Leslie Citrome Clinical Research and Evaluation Facility, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. [email protected]
&
Jan Volavka Clinical Research and Evaluation Facility, Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. [email protected]
Pages 69-88 | Published online: 10 Jan 2014

References

  • Novartis: Clozaril product information, 56th FAition of Physicians' Desk Reference, Montvale, NJ: Medical Economics Company, 2319–2323 (2002).
  • Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45, 789–796 (1988).
  • ••Classic pivotal trial of clozapine.
  • Volavka J, Czobor P Sheitman B et al Clozapine, olanzapine, risperidone and haloperidol in treatment-resistant patients with schizophrenia and schizoaffective disorder. Am. J Psychiatry 159,255–262 (2002).
  • ••The only extant double-blind, randomized controlled study comparing clozapine, risperidone and olanzapine.
  • Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J Psychiatry 158, 518–526 (2001).
  • Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.' Gun. Psychopharmacol. 17, 407–418 (1997).
  • •• Often-quoted industry-sponsored comparison study that has generated much controversy (see also [6]).
  • Conley RR, Mahmoud R A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am.j Psychiatry 158, 765–774 (2001).
  • ••Industry sponsored multicenter studyfollowing on the heels of another (see also [5]).
  • Simpson G, Romano SJ, Home RL,Weiden P Pigott T, Bari M. Ziprasidone vs. olanzpine in schizophrenia: results of a double-blind trial. Poster Presentation, 41st annual NCDEU meeting, Phoenix, AZ, USA, May 28–31 (2001).
  • Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics." Psychopharmacd 14, 409–418 (2000).
  • Conley RR, Tamminga CA, Bartko JJ et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J Psychiatry 155, 914–920 (1998).
  • Brier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Bid Psychiatry 45, 403–411 (1999).
  • Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 49, 52–63 (2001).
  • •• A noninferiority trial; this methodology is becoming more common.
  • Wirshing DA, Marshall BD, Jr., Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry 156, 1374–1379 (1999).
  • • Often-quoted study demonstrating superior efficacy of risperidone at 4, but not at 8 weeks when average daily dose was higher.
  • Bondolfi G, Dufour H, Patris M et al Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. J Psychiatry 155, 499–504 (1998).
  • •Double-blind controlled study that included treatment-intolerant patients.
  • BreierAF, Malhotra AK, Su T-P et al Clozapine and risperidone in chronic schizophrenia: effects on symptoms, patkinsonian side effects and neutoendocrine response. Am. J. Psychiatry 156, 294–298 (1999).
  • Lindenmayer JP, Volavka J, Lieberman J et al. Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open Label, Prospective Trial. J Gun. Psychopharmacol. 21, 448–453 (2001).
  • •A systematic trial of olanzapine at doses greater than 20 mg/day.
  • Sharif ZA, Raza A, Ratakonda SS. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: A retrospective analysis. J Psychiatry 61, 498–504 (2000).
  • Azorin JM, Spiegel R Remington G et al A double-blind comparative study of dozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry 158, 1305–1313 (2001).
  • Buckley P Goldstein JM, Emsley R Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. Poster Presentation, 41st annual NCDEU meeting, Phoenix, AZ, USA, May 28-31(2001).
  • Marder SR Newer antipsychotics in treatment-resistant schizophrenia. Bid Psychiatry 45, 383–384 (1999).
  • Kane JM, Marder SR, Schooler NR et al. Clozapine and haloperidol in moderately refractory schizophrenia. Arch. Gen. Psychiatry 58, 965–972 (2001).
  • •Clozapine revisted, a decade after the original pivotal trial.
  • Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am.j Psychiatry 148, 231–235 (1991).
  • Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer FLY Relationship between clinical efficacy and dozapine concentrations in plasma in schizophrenia: effect of smoking." (Yin. Psychopharmacol. 13, 383–390 (1993).
  • Spina E, Avenoso A, Facciola G et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in Patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 148, 83–89 (2000).
  • Kronig MH, Munne RA, Szymanski S et al. Plasma clozapine levels and clinical response in treatment refractory schizophrenic patients. Am. J Psychiatry 152, 179–182 (1995).
  • Potkin SG, Bera R, Gulasekararn B et al Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.' Clin. Psychiatry 55(Suppl. B), 133–136 (1994).
  • VanderZwaag C, McGee M, McEvoy JP, Freudenreich 0, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am. J Psychiatry 153, 1579–1584 (1996).
  • Simpson GM, Josiassen RC, Stanilla JK et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am. J Psychiatry 156, 1744–1750 (1999).
  • Lindenmayer JP, Apergi FS. The relationship between clozapine plasma levels and clinical response. Psychiatric Annals 26, 406–412 (2000).
  • Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am. J Psychiatry 151, 825–835 (1994).
  • ••Pivotal trial of risperidone.
  • Chouinard G, Jones B, Remington G et al A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin. Psychopharmacd 13, 25–40 (1993).
  • ••Pivotal trial of risperidone.
  • Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br. J Psychiatry 166, 712–726 (1995).
  • Potkin SG, Gutierrez R Safety and efficacy of once-daily risperidone in the treatment of schizophrenia. Abstract. 150th Annual Meeting of the American Psychiatric Association, San Diego, CA, USA May 17–22, (1997).
  • Spina E, Avenoso A, Facciola G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 153, 238–243 (2001).
  • •Important data demonstrating lack of correlation between plasma levels of risperidone and clinical improvement.
  • Beasley CM, Jr., Tollefson G, Tran P, Satterlee W Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14,111–123 (1996).
  • ••Pivotal trial of olanzapine.
  • Chong S-A, Remington G. Plasma olanzapine and clinical response.' Chn. Psychopharmacot 19,192–194 (1999).
  • Hiemke C, Gerek S, Weigmann H, Hamer S. Monitoring serum levels of olanzapine. Int. J. Neuropsychopharmacd 3\(Suppl. 1), S158—S158 (2000).
  • Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial." Chn. Psychopharmacot 21,14–20 (2001).
  • •First indication that a threshold olanzapine level may be necessary for optimal response.
  • Eli Lilly and Company. Zyprexa product information, 56th FAition of Physicians' Desk Reference, Montvale, NJ: Medical Economics Company, 1973-1978 (2002).
  • Beasley CM, Jr, Beuzen J-N, Birkett MA, Kiesler GM, Tollefson GD, Wood AJ. Olanzapine versus clozapine: an international double-blind study of the treatment of resistant schizophrenia. Abstract. 152nd Annual Meeting of the American Psychiatric Association May 15–20,136–137 (1999).
  • Sheitman BB, Lindgren JC, Early J, Sved M. High-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry 154,1626–1626 (1997).
  • Mountjoy CQ, Balcla chino AM, Stubbs JH. British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry 156,158–159 (1999).
  • Reich J. Use of high-dose olanzapine in refractory psychosis. Am. J. Psychiatry 156, 661 (1999).
  • Fanous A, Lindenmayer JP. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. I Chn. Psychopharmacot 19,275–276 (1999).
  • Arvanitis LA, Miller BG and the Seroquel Trial 13 Study Group. Multiple fixed doses of `Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiatry 42,233–246 (1997).
  • ••Pivotal trial of quetiapine.
  • Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG and the Seroquel Study Group. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry 54,549–557 (1997).
  • ••Pivotal trial of quetiapine.
  • Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. 96,265–273 (1997).
  • Reinstein MJ, Sonnenberg JG, Chasanov MA et al. Comparative efficacy and tolerability of quetiapine at high and low doses. Abstract. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 5–10 (2001).
  • Wilson WH, Claussen AM. 18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital. Psychiatric Services 46,386–389 (1995).
  • Ratey JJ, Leveroni C, Kilmer D et al The effects of clozapine on severely aggressive psychiatric in-patients in a state hospital." Chn. Psychiatry 54,219–223 (1993).
  • Chiles JA, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp. Comm. Psychiatry 45,269–271 (1994).
  • Mallya AR, Roos PD, Roebuck-Colgan K. Restraint, seclusion and clozapine. I Chn. Psychiatry 53,395–397 (1992).
  • Spivak B, Mester R, Wittenberg N et al Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Chn. Neuropharmacol. 20,442–446 (1997).
  • Maier GJ. The impact of clozapine on 25 forensic patients. Bull. Am. Acad. Psychiatry Law 20, 297–307 (1992).
  • Ebrahim GM, Gibler B, Gacono CB et al. Patient response to clozapine in a forensic psychiatric hospital. Hosp. Comm. Psychiatry 45,271–273 (1994).
  • Volavka J, Zito JM, Vitrai J et al. Clozapine effects on hostility and aggression in schizophrenia.' Chn. Psychopharmacot 13, 287–289 (1993).
  • Buckley P, Bartell J, Donenwirth MA et al Violence and schizophrenia: clozapine as a specific anti-aggressive agent. Bull Am. Acad. Psychiatry Law. 23,607–611 (1995).
  • Citrome L, Volavka J, C,zobor P et al. Effects of clozapine, olanzapine, risperidone and haloperidol on hostility among patients with schizophrenia. Psychiatric Services 52, 1510–1514 (2001).
  • ••The only extant double-blind controlledcomparison of three atypical antipsychotics and haloperidol and effect on hostility.
  • Czobor 1 Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia." Clin. Psychopharmacd 15,243-249(1995).
  • Chengappa KNR, Levine J, Ulrich R et al Impact of risperidone on seclusion and restraint at a state psychiatric hospital. Can. Psychiatr. 45,827–832 (2000).
  • Buckley PF, Ibrahim ZY, Singer B, On B, Donenwirth K, Brar PS. Aggression and schizophrenia: efficacy of risperidone. Am. Psychiatry Law 25,173–181 (1997).
  • Beck NC, Greenfield SR, Gotham H, Menditto AA, Stuve P, Hemme CA. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. jAm. Acad. Psychiatry Law 25, 461–468 (1997).
  • Cantillon M, Goldstein JM. Quetiapine fumarate reduces aggression and hostility in patients with schizophrenia. New Research Poster NR444. American Psychiatric Association 1998 Annual Meeting, Toronto, Ontario, Canada, May 30-June 4(1998).
  • Citrome L, Krakowski M, Greenberg WM, Andrade E, Volavka J. Anti-aggressive Effect of Quetiapine in a Patient with Schizoaffective Disorder. J. Clin. Psychiatry 62,901 (2001).
  • Brooks JO. Successful outcome using quetiapine in a case of treatment-resistant schizophrenia with assaultive behavior. Schiz. Res. 50,133–134 (2001).
  • Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J. Clin. Psychiatry 62\(Suppl. 2), 17–21 (2001).
  • Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia." Clin. Psychiatry 59\(Suppl. 3), 8–14 (1998).
  • Volavka J, Citrome L Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schiz. Res. 35, S23—S33 (1999).
  • Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders." Clin. Psychiatry 6, 411–417 (1995).
  • Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am. j Psychiatry 153, 759–764 (1996).
  • Tohen M, Sanger TM, McElroy SL et al. Olanzapine vs. placebo in the treatment of acute mania. Am. j Psychiatry 156, 702–709 (1999).
  • Tohen M, Jacobs TG, Grundy SL et idEfficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 57, 841–849 (2000).
  • Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen ME Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. j Psychiatry 62, 273–281 (2001).
  • Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. 1Veuropharmacol. 21, 176–180 (1998).
  • Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann. Clin. Psychiatry 11, 137–140 (1999).
  • Regier DA, Farmer ME, Rae DS et al Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JANIA 264, 2511–2518 (1990).
  • ••Classic epidemiological study.
  • Citrome L, Volavka J. Management of Violence in Schizophrenia. Psychiatric Ann. 30, 41–52 (2000).
  • •Recent review.
  • Swartz MS, Swanson JW, Hiday VA, BorurnR., Wagner HR, Bums BJ. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am j Psychiatry 155, 226–231 (1998).
  • •Important cautionary article.
  • Albanese MJ, Khantzian EJ, Mutphy SL, GreenAl. Decreased substance use in chronically psychotic patients treated with clozapine. Am. Psychiatry 151, 780–781 (1994).
  • Buckley I.; Thompson 1 y L, Meltzer HY Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am. J. Psychiatry 151, 385–389 (1994).
  • •• An early, influential report.
  • Marcus P, Snyder R Reduction of comorbid substance abuse with clozapine. Am.j Psychiatry 152, 959 (1995).
  • Drake RE, Xie H, McHugo GJ, Green Al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr. Bull. 26,441–449 (2000).
  • Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis.' Nerv. Ment. Dis. 182, 591–592 (1994).
  • Zimmet SV, Strous RD, Burgess ES, Kohnstamrn S, Green Al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. j Clin. Psychopharmacol. 20, 94–98 (2000).
  • Buckley PE Substance abuse in schizophrenia: a review." Clin. Psychiatry Suppl. 59, 26–30 (1998).
  • Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients." Clin. Psychiatry 60\(Suppl. 12), 43–46 (1999).
  • Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Olanzapine treatment for patients with schizophrenia and substance abuse. j Substance Abuse Treatment 21, 217–221 (2001).
  • Buckley PE Novel antipsychotic medications in the treatment of comorbid substance abuse in schizophrenia." Substance Abuse Treatment 15, 113–116 (1998).
  • Green AT, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv. Rev. Psychiatry 6, 287–296 (1999).
  • ••Excellent and current tutorial/review.
  • Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr. Res. 33, 95–101 (1998).
  • Bilder R/VI, Goldman RS, Robinson D et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. j Psychiatry 157, 549–559 (2000).
  • Spohn HE, Strauss ME Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. j Abnorm. Psychol. 98, 367–380 (1989).
  • Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25, 201–222 (1999).
  • •Current review.
  • Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Ain.j Psychiatry 158, 176–184 (2001).
  • Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can. j Psychiatry 42, 255–264 (1997).
  • ••Excellent overview of this topic.
  • Daniel DG, Goldberg TE, Weinberger DR et al. Different side effect profiles of risperidone and clozapine in 20 out-patients with schizophrenia or schizoaffective disorder: A pilot study. Am. j Psychiatry 153, 417–419 (1996).
  • Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 30, 35–42 (1997).
  • Lindenmayer JP, Iskander A, Park M et at Clinical and neurocognitive effects of clozpaine and risperidone in treatment-refractory schizophrenics: A prospective study." Clin. Psychiatry 59, 521–527 (1998).
  • Meltzer HY. The role of serotonin in antipsychotic drug action. 1Veuropsychopharmacology 21, 106S-115S (1999).
  • Meltzer HY, McGurk SR The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233–255 (1999).
  • ••Influential article by well-known leaders inthe field.
  • Purdon SE, Jones BD, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch. Gen. Psychiatry 57, 249–258 (2000).
  • •Although sample size is small and restricted to early phase of illness, this study has been influential.
  • Harvey PD. Cognitive effects of risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Presented at the Annual Meeting of the American Psychiatric Association, Chicago, IL, USA (2000).
  • Bilder RM, Goldman RS, Volavka J et al Neurocognitive Effects of Clozapine, Olanzapine, Risperidone and Haloperidol in Patients with Chronic Schizophrenia, Poster Presentation, ACNP Annual Meeting, Hawaii, USA, December (2001).
  • Gutierrez R, Lee PI, Huang ML, Woestenborghs R Risperidone: effects of formulations on oral bioavailability. Pharmacotherapy 17, 599–605 (1997).
  • Janssen Pharmaceutica. Risperclal product information, 56th FAition of Physicians' Desk Reference, Montvale, NJ: Medical Economics Company, 1796–1800 (2002).
  • Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus im. haloperidol and im. lorazepam for treatment of psychotic agitation.' Clin. Psychiatry 62, 153–157 (2001).
  • Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form." Pharm. Pharmacol. 50, 375–382 (1998).
  • Chue IJones B, Taylor C Dissolution profile and safety of olanzapine orally-disintegrating tablet in patients with schizophrenia. Schizophr Res. 41(1 SI), 192 (2000).
  • Hay LK, Hill A, Kinon BJ et al. Efficacy of olanzapine orally-disintegrating tablet in the treatment of acutely ill non-compliant schizophrenic patients. Schizophr. Res. 49, 231 (2001).
  • Citrome L. Atypical antipsychotics for acute agitation: new im. options offer advantages. Postgraduate Medicine. (2002, in press).
  • Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.j Clin. Psychiatry 62, 12–18 (2001).
  • Reeves KR, Swift RH, Harrigan EP: Ziprasidone im. 10 mg and 20 mg in acute agitation. Poster NR494. American Psychiatric Association 151st Annual Meeting, Toronto, Canada, June 3 (1998).
  • Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with im. haloperidol in the treatment of acute psychosis.' Clin. Psychiatry 61, 933–941 (2000).
  • Wright P Birkett M, David SR et al Double-blind, placebo-controlled comparison of im. olanzapine and im. haloperidol in the treatment of acute agitation in schizophrenia. Am. J Psychiatry 158, 1149–1151 (2001).
  • Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J Psychiatry 156, 1686–1696 (1999).
  • McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Can. J Psychiatry 46, 273–281 (2001).
  • Liebzeit KA, Markowitz JS, Caley CE New onset diabetes and atypical antipsychotics. Eur. Neuropsychopharmacol.11, 25–32 (2001).
  • Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Bia Psychiatry 44, 778–783 (1998).
  • Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses-a comparison between different antipsychotic agents. Psychopharmacology (Berl). 154, 205–212 (2001).
  • Dixon L, Weiden P Delahanty J et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26, 903–912 (2000).
  • Burke JP Williams K, Gaskill SP Hazuda HP Haffner SM, Stern MP Rapid rise in the incidence of Type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch. Intern. Med. 159, 1450–1456 (1999).
  • Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension. Arch. Gen. Psychiatry 58, 1172–1176 (2001).
  • Cavazzoni 1 Baker RW, Kwong K et al A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States. Poster presentation, 41st New Clinical Drug Evaluation Unit meeting, Phoenix, AZ, USA May 28–31 (2001).
  • Gianfrancesco F, Gm ±. A, Mahmoud R, Markowitz J, Nasrallah HA. Association of new-onset diabetes and antipsychotics: findings from a large health plan database. Poster presentation, 41st New Clinical Drug Evaluation Unit meeting, Phoenix, AZ, USA, May 28–31 (2001).
  • Wilson DR Hammond CC, Buckley PF, Petty F, Femandes P Atypical antipsychotics and hyperglycemia: an analysis of 11,994 persons treated in Ohio DMH hospitals, 1994–2001. Poster presentation, 40th Annual Meeting of the ACNP, Hawaii, USA, December 9–13 (2001).
  • Breier A, Kwong K, Hombuckle K et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United Kingdom. Poster presentation, 40th Annual Meeting of the ACNP, Hawaii, USA, December 9–13 (2001).
  • Czobor P Volavka J, Sheitman B et al. Antipsychotic-induced Weight Gain and Therapeutic Response: A Differential Association. J. Clin. Psychopharmacot (2002, in press).
  • Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes and sudden death. Am. J Psychiatry 158, 1774–1782 (2001).
  • ••Excellent current review.
  • Lischke V, Behne M, Doelken 1 Schledt U, Probst S, Vettermann J. Droperidol muses a dose-dependent prolongation of the Qf interval. Anesth. Anak 79, 983–986 (1994).
  • Meltzer HY, Goode DJ, Schyve PM et al. Effect of clozapine on human serum prolactin levels. Am.j Psychiatry 136, 1550–1555 (1979).
  • Goff DC, Posever T, Herz et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin. Pschopharmacol. 18, 296–304 (1988).
  • Crawford AM, Beasley CM, Jr., Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 25, 41–54 (1997).
  • Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropoichopharmacology 20, 491–505 (1999).
  • Keck P Jr, Buffenstein A, Ferguson J et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 140, 173–184 (1998).
  • Jafee AB, Levine J. Polypharmacy or coprescribing: combining antipsychotic medications. Poster presentation, 41st New Clinical Drug Evaluation Unit meeting, Phoenix, AZ, USA, May 28–31 (2001).
  • McCarthy RI-I, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 28, 61–63 (1995).
  • Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin. Drug Invest. 18, 99–104 (1999).
  • Citrome L, Levine J, Allingharn B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatric Services 51, 634–638 (2000).
  • Casey DE, Daniel D, Tracy K, Wozniak P, Sommerville K. Improved antipsychotic effect of divalproex combined with risperidone or olanzapine for schizophrenia. Poster presentation, 26th Biennial Congress of the World Federation for Mental Health, Vancouver, BC, Canada, July (2001).
  • Atre-Vaidya N, Taylor MA. Effectiveness of lithium in schizophrenia: Do we really have an answer?' Clin. Psychiatry 50, 170–173 (1989).
  • Citrome L Differential diagnosis of psychosis. Postgraduate Med. 85, 273–280 (1989).
  • Wilson WH, Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double-blind, placebo-controlled parallel design clinical trial. Psychopharmacology 111, 359–366 (1993).
  • Bristol-Myers Squibb Company, Otsuka Pharmaceutical Company Ltd. Press Release. November 7, 12:05 AM EST (2001).
  • Lawler CP, Prioleau C, Lewis MM et al Interactions of the novel antipsychotic aripiprazole (OPC.-14597) with dopamine and serotonin receptor subtypes. 1Veuropsychopharmacology 20, 612–627 (1999).
  • Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: overview of Phase II results. Poster presentation, ACNP 36th Annual Meeting, Hawaii, USA, December 8–12 (1997).
  • Kane J, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophr. Res. 41, 39 (2000).
  • Zimbroff DL, Saha AR, Afi MW Ingenito G, Dunbar GC, Carson WH. A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Poster presentation, 41st New Clinical Drug Evaluation Unit meeting, Phoenix, AZ, USA, May 28–31 (2001).
  • Kalkman HO. The broad spectrum profile of Zomaril tailored for the treatment of psychotic disorders (1999). In Novartis Pharma AG. Iloperidone: An Overview of Recent Abstracts and Posters. 7th World Congress of Biological Psychiatry, Berlin, Germany, July 1–6 (2001).
  • Matkovitis-Gupta T, Cucchiaro J, El-Bizri H et al. Safety and efficacy of iloperidone in patients with psychotic disorders: a randomized double-blind multicenter study. Schizophr. Res. 49, 238 (2001).
  • Kalali A, Lasser R, Campbell B et al. The management of cultural differences and the importance of safety minitoring in global studies: the ReALIZe clinical program. Poster presentation, ACNP 39th Annual Meeting, Puerto Rico, December 11–15 (2000).
  • Cucchiari J, Nann-Verontica E, Lasser R et al. A randomized, double-blind, multicenter Phase III study of iloperidone versus haloperidol and placebo in patients with schizophrenia or schizoaffective disorder. Schizophr. Res. 49, 223 (2001).
  • Lasser RA, Campbell B, Hourani J, Gharabawi M. A prospective double-blind, randomized, parallel-group, placebo-controlled study of iloperidone (0.5 to 6.0 mg/d) in the treatment of psychotic and behavioral symptoms in elderly patients with dementia. Poster presentation, 41st New Clinical Drug Evaluation Unit meeting, Phoenix, AZ, USA, May 28-31(2001).
  • Pfizer, Inc. Geodon product information, 56th Fflition of Physicians' Desk Reference, Montvale, NJ, USA: Medical Economics Company, 2688–2692 (2002).

Websites

  • Pfizer, Inc. Briefing Document for Ziprasidone Mesylate for Intramuscular Injection, FDA Psychopharmacological Drugs Advisory Committee, February 15, 2001 (available at www.fda.gov/ohrms/ dockets/ac/01/briefing/3685b2.htm).
  • ••Comprehensive overview provided by themanufacturer to the FDA and now in the public domain.
  • Eli Lilly and Company. Briefing Document for Zyprexa IntraMuscular (olanzapine for injection), FDA Psychopharmacological Drugs Advisory Committee, January 11, 2001 with Addendum February 14, 2001 (available at www.fda.gov/ohrms/dockets/ ac/01/briefing/3685b 1.htm) .
  • ••Comprehensive overview provided by themanufacturer to the FDA and now in the public domain.
  • Citrome L Get ready for a new marketing war. The Bulletin of the New York State Psychiatric Association. Available at www.nyspsych.org/bulletin. 44(1), 2(2001).
  • United States Food and Drug administration. FDA Talk Paper TO1-62. FDA strengthens warnings for droperidol. Available at www.fda.gov/bbs/topics/ ANSWERS/2001/ANS01123.html. December 5(2001).
  • World Health Organization. Droperidol voluntary withdrawal: prolongation of the QT interval. WHO Pharmaceuticals Newsletter. Available at www.who.int/ medicines/library/pnewslet/npn0101.html. No. 1(2001).
  • Janssen Pharmaceutic. New data show efficacy for first injectable, long-acting atypical antipsychotic. Press Release available at http://us.janssen.com/feature_artides/ feature05022001.html. May 2(2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.